Shots:
- BioAtla and GATC Health announce into a $40M special purpose vehicle (SPV) transaction to advance ozuriftamab vedotin (Oz-V), a CAB-ROR2-ADC, into a registrational P-III study for 2L+ oropharyngeal squamous cell carcinoma (OPSCC)
- Under the agreement, BioAtla will receive $5M upfront to support operations and P-III study execution, with the remaining $35M expected to close in Q1’26; BioAtla will retain 65% ownership of Oz-V across all solid tumor indications
- BioAtla will lead P-III study execution through data readout for potential accelerated approval, with enrollment anticipated to begin in early 2026; Oz-V has received US FDA Fast Track Designation for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Ref: BioAtla |Image: BioAtla and GATC Health | Press Release
Related News: Intelligent Bio Solutions and Syrma Johari MedTech Collaborate to Advance Global Production Capability and Margin Expansion
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
